MRI T1 Relaxation Time in Rectal Cancer

The goal of this observational study is to learn about the T1 relaxation time and T1 relaxation time properties of the disease in people with locally advanced rectal cancer. The main question it aims to answer is:

Does MRI T1 relaxation time have a high diagnostic performance in recognizing fibrosis as a complete response to neoadjuvant treatment of rectal cancer?

Participants will receive standard neoadjuvant treatment and be part of the standard examination programme regarding rectal cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rectal Cancer Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Locally Advanced Rectal Carcinoma Neoplasms Neoplasms by Site Rectal Diseases Rectal Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vejle Hospital

Vejle, Jylland, 7100, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

rectal cancer, age >18 years

Exclusion criteria

contraindications for MRI (pacemaker, claustrophobia, implanted medical injectors and nerve stimulators),
previous radiochemotherapy or another disease which investigator judges inappropriate for the persons continued participation.

Treatment and study plan

Primary outcomes

Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.

Time frame: 6 to 8 weeks.

An MRI T1 relaxation time-map is performed on each participant. The data is transferred to IntelliSpace-software for measurement and mapping. It is measured in miliseconds (ms) before and after neoadjuvant treatment.

Sponsors and collaborators

Lead sponsor

Vejle Hospital

Other

Registry information

Official study title

MRI T1 Relaxation Times in Evaluating Neoadjuvant Treatment of Rectal Cancer

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: May 25, 2023
Registry last updated: Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting